THOMAS PAUL 4

What Happened

• Thomas Paul, a director of TELA Bio, received equity awards on June 9, 2026 totaling 58,485 units across restricted stock units (RSUs) and stock options. The grants were reported at $0.00 per share (no cash paid by the insider).
• Breakdown: 11,925 RSUs, 11,675 RSUs, 17,550 option units (derivative), and 17,335 option units (derivative). These were reported as awards (transaction code A).

Key Details

• Transaction date: June 9, 2026; Form 4 filed June 11, 2026 (filed timely).
• Reported price: $0.00 for all grants (typical for awards/grants).
• Shares/units after transaction: Not disclosed in the filing.
• Vesting notes:
  • 11,925 RSUs vest in three equal annual installments beginning June 9, 2027 (subject to continued service).
  • 11,675 RSUs vest on the earlier of June 9, 2027, the next annual meeting, or a Change in Control (subject to continued service).
  • 17,550 option units vest in 36 equal monthly installments beginning June 9, 2026 (subject to continued service).
  • 17,335 option units vest on the earlier of June 9, 2027, the next annual meeting, or a Change in Control (subject to continued service).

Context

• These grants are compensatory awards to a director and vest over time or upon specified events; they are not open-market purchases or sales. Such awards are common director compensation and do not by themselves indicate immediate buying or selling activity.